



Aktiespararna

F.R. Martelet, M.D., CEO

14 March 2022

Forward-looking statement



Important notice

The information in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require preparation of further prospectuses or other offer documentation, or be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.

No representation or warranty expressed or implied is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinion contained herein.

The information in this presentation may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, reproduction, or disclosure of this information in whole or in part is unauthorized. Failure to comply with this directive may result in a violation of the Securities Act or the applicable laws of other jurisdictions.

Forward looking statements

This presentation contains forward-looking statements that reflect management's current views with respect to certain future events and potential financial performance. Although Oasmia believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. Accordingly, results could differ materially from those set out in the forward-looking statements as a result of various factors.

Important factors that may cause such a difference for Oasmia include but are not limited to: (i) the macroeconomic development, (ii) change in the competitive climate and (iii) change in interest rate level.

This presentation does not imply that Oasmia has undertaken to revise these forward-looking statements, beyond what is required by applicable law or applicable stock exchange regulations if and when circumstances arise that will lead to changes compared to the date when these statements were provided.

A listed Swedish oncology-focused specialty pharmaceutical company


- Stock exchange and ticker: Nasdaq Stockholm (OASM)
- Market capitalization as at 7 Mar. 2022: 687 MSEK



Lead drug **Apealea[®]** (paclitaxel micellar) being launched by **partner in Europe**; first royalties anticipated H2 2022



String of pearls' strategy to build comprehensive oncology pipeline through in-licensing & M&A



Emerging portfolio focused on **hard-to-treat and late-stage cancers** with limited treatment options



First-in-licensed drug **Cantrixil** **Phase 2 in preparation**; *'pipeline within a molecule'* potential

Our two lines of business

Oncology R&D

in-licensed & wholly-owned
development-stage assets:

- Cantrixil
- Docetaxel micellar
- Strategic pipeline development (string of pearls)



Commercial

revenues from out-licensed
products and technologies:


- Apealea[®]
- XR-17[™]/ XR-18 drug delivery technologies
- Animal health assets



Substantial recent progress in our transformation journey

New strategy & focus

Development of internal and in-licensed products
Revenues from out-licensed products and technologies



Capabilities and experience to build a diversified oncology pipeline

Business Development	Partnering	Pipeline	Regulatory	Clinical	Product Development
----------------------	------------	----------	------------	----------	---------------------



Francois Martelet, MD
Chief Executive Officer



Fredrik Järsten*
Chief Financial Officer



Reinhard Koenig, MD
Chief Scientific Officer



Kia Bengtsson
Head of Clinical Development



Johanna Röstin
Head of Regulatory Affairs



Kai Wilkinson, PhD
Chief Technology Officer



Head of Quality

Head of R&D and Manufacturing


Pharmacovigilance Officer

Emerging oncology portfolio ready for further expansion

Product	Indication	Pre-clinical	Phase 1	Phase 2	Phase 3	Registration / approval	Commercial Launch	Geography	
Apealea [®] (paclitaxel micellar)	Ovarian cancer	→							EU/EEA
Apealea [®] (paclitaxel micellar)	Ovarian cancer	→						USA	
Cantrixil IP	Ovarian cancer	→						Global	
Docetaxel micellar	Prostate cancer	→						EU/EEA	
Cantrixil IV	Ovarian cancer	→						Global	



XR-17™/XR-18 – proprietary solubilization platform targeting improved safety and efficacy



- ✓ High drug delivery capability
- ✓ Shorter infusion time^{1,2}
- ✓ Superior solubility
- ✓ Enhanced API bioavailability
- ✓ Validated safety in cancer ¹
- ✗ No or limited need for pre-medication¹
- ✗ No alcohol, Crem. EL, Polys.80, human albumin

Potential use in cancers:

- ✓ Ovarian
- ✓ Prostate
- ✓ Bladder
- ✓ Lung
- ✓ Breast


Apealea® - an improved treatment option in ovarian cancer



- Solvent-free IV formulation of paclitaxel using XR-17™
 - No polyoxyethylated castor oil or dehydrated alcohol
 - No glucocorticosteroids required pre-medication
- Shorter infusion and overall 'chair' time
- Approved in EU for treatment of first relapse ovarian cancer¹
- Targeting patients unable to tolerate solvent-based paclitaxel

	 apealea® <small>paclitaxel (micellar)</small>	Taxol®	 Abraxane® <small>(nanoparticle albumin-bound paclitaxel)</small>	Lipusu®	Genexol-PM® Korea
Company	 Oasmia	 Bristol Myers Squibb	 Celgene	 LUYE PHARMA	 samyang Biopharm
Indication	Ovarian Cancer	Ovarian Cancer Breast Cancer NSCLC	Breast Cancer	Ovarian Cancer Breast Cancer NSCLC	Ovarian Cancer Breast Cancer NSCLC
Infusion Solution	Micellar Solution	Emulsion	Colloidal Suspension	Liposome	Micellar Solution
Particle Size	25nm	10-22nm	130nm	400nm	~25nm
Excipient	XR-17™ (Oasmia's own proprietary drug delivery technology)	Cremophor EL	Human Albumin	Lecithin / Cholesterol	PEG-PDLLA
Dose	250mg/m ²	175mg/m ²	260mg/m ²	175mg/m ²	260mg/m ²
Ratio (Excipient : API)	1.3 : 1.0	88.0 : 1.0	9.0 : 1.0	-	5.0 : 1.0
Infusion Time	1h	3h	<1h	3h	0.5h
Pre-medication	Not mandatory	Yes	No	Yes	Not mandatory
Hypersensitivity	No	Yes	No	Yes	No

Apealea® - milestones & royalties



**Global agreement with US-based Elevar Therapeutics,
a subsidiary of South Korea's HLB, worth up to \$698m + royalties (incl. \$20m upfront)**

Apealea® - partnered with Inceptua in Europe

25 years of specialty pharma commercial expertise



- An international specialty care and rare disease pharma company with commercialization focus on Europe, and the Middle-East
- Experts in commercialization of high unmet need pharma products
- Global supply, quality and regulatory capabilities
- Strong management team with deep industry experience

Inceptua Group

Pharmaceutical Company & Service Partner

- Inceptua Pharma is a part of Inceptua Group
- The Group consists of the three business areas: Inceptua Pharma, Inceptua Clinical Trial Supply, and Inceptua Early Access
- Well-established pharma company and service partner with 25 years on the market
- Offices across Europe, North America, and Asia

Apealea[®] - first launches in UK & Germany




Apealea[®] go-to-market global strategy developed

- Patient access, commercial, medical and community engagement tactics ready to be executed
- Publication plans developed and ready to be implemented
- Apealea[®] key advertising campaign messages finalized and ready to be launched

First royalties and milestones for Oasmia anticipated by H2 2022

● H1 2022 launch




Cantrixil – positive Phase IB results



- Progression free survival* data in multiple relapse ovarian cancer presented at AACR 2021
- Across Parts A and Part B 16/25 (64%) patients were evaluable for efficacy*
- Best overall response† after monotherapy:
 - Stable disease 9/16 (56%)
- Best overall response† after combination therapy:
 - Complete response (N=1, platinum-resistant)
 - Partial response (N=2, platinum-resistant, platinum-refractory)
 - Stable disease (N=6)

Objective
Response
Rate 3/16:



Disease
Control
Rate 9/16:




Cantrixil – gearing up for Phase II



- **Clinical Advisory Board met September 2021**
 - KOLs from Europe, Australia and US including GOG Foundation, Inc.*
 - Guidance on Phase 2 trial design
- **Initiation of interactions with regulators**
 - Meetings with FDA, EMA and Sweden’s MPA to be held during 2022
 - Discussion of trial design, endpoints, appropriate data for filing and regulatory pathways
- **Securing study drug supply**
 - Sourcing Contract Manufacturing Organization (CMO) for Phase II supplies
 - Technical transfer and scale up
- **Preparing for Phase II initiation**
- **Exploring *pipeline in a product* potential in other cancers in cancers that express CD44+**

Docetaxel micellar – Phase IB initiated

- Phase IB trial initiated by SAKK in advanced prostate cancer
- Open-label, multi-center, single-stage trial at 3 major hospitals in Switzerland
- SAKK seeking to add additional site to accelerate recruitment
- Targeting 18 chemotherapy-naive patients with **metastatic castration-resistant prostate cancer (mCRPC)** with adequate bone marrow, liver and renal function
- Docetaxel micellar
 - i.v. formulation of docetaxel, standard of care for advanced prostate cancer, approved for many solid malignancies
 - XR-17™ utilized to enable administration without solubility enhancers



XR-17™/XR-18 – next generation development



Platform expansion & next generation solubilization enhancer in development

- XR-17™ successfully employed in Apealea®
- Karolinska Institutet undertaking research into biological interactions of XR-17™ with cellular systems in-vitro
- In-house development of next-generation XR-18 making good progress
- Promising novel candidate identified and synthesized for new formulation
- Testing underway in combination with widely-used oncology compound




**Karolinska
Institutet**

Q4 report – delivering cost savings and careful cash management

- Net sales of 9.6 MSEK
 - Drug products shipped to Elevar
- Operating costs totalled MSEK 31.4
 - Significant reduction since Q4 2020 and for the full year cost savings amounted to MSEK 110
- Operating loss of -2.1 MSEK
- Operating cashflow of MSEK -44.6
 - If adjusted for the non-recurring payment of MSEK 25 in relation to the settlement, operating cashflow in Q4 was approx. MSEK -19.6
- Cash and cash equivalents amounted to MSEK 97 at the end of the quarter
- No borrowings as per 31 December, implying a net liability of MSEK -97

Significant reduction in Opex (MSEK)




Background and rationale for the rights issue



Background and rationale

- After a successful turn-around, Oasmia is well-positioned to execute on its string-of-pearls strategy
- The rights issue aims to strengthen Oasmia's financial position to enable the company to achieve its strategic objectives

Our mission is to create a Nordic oncology powerhouse focused on hard-to-treat cancers




Overview of the rights issue process

Rights issue terms



High level overview of the rights issue process



Our new identity launching in late March

The Vivesto logo, featuring a stylized blue and green icon of a person with arms raised to the left of the word "Vivesto" in a large, bold, blue, sans-serif font.


Vivesto

*"Our new brand marks the improved prospects
for our business following completion of
the first steps in our transformation"*

**To create a Nordic oncology
powerhouse focused on
hard-to-treat cancers**

String of pearls strategy – leveraging our strengths

Adding new oncology programmes
with cutting edge science



Summary

Opportunity to create a Nordic oncology powerhouse focused on hard-to-treat cancers



Capabilities and experience in place to build a diversified oncology pipeline



String of pearls strategy to build critical mass



Multiple shots on goal through diversified mechanisms of action targeting varied tumor types



A strong platform for innovative partners & high potential assets



Positioned to attract **international institutional specialist investors**





Thank you

Oasmia Pharmaceutical AB (STO: OASM)
Vallongatan 1
752 28 Uppsala
Sweden

 +46 018-50 54 40

 IR@oasmia.com

 www.oasmia.com

 www.linkedin.com/company/oasmia-pharmaceutical-ab

 www.twitter.com/Oasmia